ROME, November 3, 2021 / PRNewswire / – ReiThera Srl, a biotechnology company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and drugs for advanced therapies, today announces that it has been awarded a 1.4 million US dollars Bill & Melinda Gates Foundation grant for the generation of new vaccine candidates based on the proprietary GRAd platform.
The funded program will focus on two key objectives:
- Develop innovative second generation vaccine candidates capable of providing broader coverage against variants of concern of SARS-CoV-2 and
- Support the Bill & Melinda Gates Foundation HIV Vaccine Initiative to generate new vaccine candidates
The result of this research is designed to primarily benefit people living in low- and middle-income countries, especially in Africa, who are disproportionately affected by HIV and currently have no or very limited access to effective COVID-19 vaccines.
Stefano Coloca, CTO and Co-Founder of ReiThera, said, “We are delighted that ReiThera has received this grant from the prestigious Bill & Melinda Gates Foundation, which will also allow us to access their network of very experienced scientific collaborators. The grant validates the potential of our new GRAd vector technology to develop much-needed vaccines for both new variants of COVID-19 and HIV. I look forward to working with our world-renowned partners as we strive to generate these new vaccines, which are expected to have a very positive impact on the lives of people in low- and middle-income countries. ”
ReiThera has previously developed GRAd-COV2, a candidate vaccine against SARS-CoV-2 based on the novel replication-defective Gorilla adenoviral vector encoding the full-length coronavirus spike protein. The GRAd vector belongs to the adenovirus species C which is considered to be the most potent vaccine vector and has a low seroprevalence in humans.
Recent phase 1 and 2 studies have shown that GRAd-COV2 is safe and well tolerated in adults and the elderly, as well as in subjects with co-morbidities, with seroconversion rates greater than 93% after a single dose and greater than 99% with two doses. diet. These results support the further clinical development of the candidate vaccine with a phase 3 study.
At the same time, ReiThera has also invested significantly in its CDMO organization by expanding the existing GMP area and acquiring advanced technologies, including stirred tank bioreactors supporting a working volume of up to 3000L. This installation is intended to be used for the production of GRAd-COV2 vaccine on a large scale.
As the GRAd-COV2 manufacturing process is based on disposable technologies, it could easily be transferred to external sites for local production in countries where demand for this new vaccine is greatest.
About ReiThera Srl
ReiThera Srl is a biotechnology company dedicated to technological development, GMP manufacturing and clinical translation of genetic vaccines and drugs for advanced therapies. The company’s management and scientific teams have developed a highly innovative technological platform based on simian adenovector vaccines against several infectious diseases, such as RSV and Ebola.
ReiThera is led by an experienced management team who have worked together for many years at previous successful companies, including Okairos (acquired by GSK), and have long-standing expertise in the evolutionary processes for manufacturing viral vectors, supported by a cGMP facility including filling room and quality control laboratories.
ReiThera has its head office, R&D laboratories and GMP facilities in Rome, Italy.
For more information see: www.reithera.com
Antonella Folgori, Managing Director
MEDiSTRAVA Consulting – International Press
Sylvie Berrebi, Mark Swallow PhD, George Underwood
+44 (0) 7714306525 / +44 (0) 7903737703
Comin & Partners – Italian Press
+39 349 2840676
SOURCE ReiThera Srl